[News] Apalutamide shows efficacy in prostate cancer

The androgen receptor inhibitor apalutamide significantly improves metastasis-free survival in patients with non-metastatic castration-resistant prostate cancer, according to a recent study.

Source: The Lancet Oncology - February 15, 2018 Category: Cancer & Oncology Authors: Elizabeth Gourd Tags: News Source Type: research